Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage

In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth

(2014) Aikaterini Pistiki et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth

(2013) S. C. Shah et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth

(2013) C. Jacobs et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis

(2012) Wai–Kit Lo et al.   Clinical Gastroenterology and Hepatology

The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome

(2012) Emmannouil Pyleris et al.   DIGESTIVE DISEASES AND SCIENCES

Peripheral Mechanisms in Irritable Bowel Syndrome

(2012) Michael Camilleri   NEW ENGLAND JOURNAL OF MEDICINE

Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture

(2011) R. S. Choung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of long-term PPI treatment on producing bowel symptoms and SIBO

(2010) Debora Compare et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS

(2010) D. Yu et al.   GUT